BioLife Solutions (BLFS) files 8-K: Q3 2025 results press release

BioLife Solutions (BLFS) filed an 8-K announcing Q3 2025 results.

Rhea-AI Filing Summary

BioLife Solutions (BLFS) filed an 8-K announcing Q3 2025 results. The company reported that it issued a press release with unaudited financial results and operational highlights for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1.

The filing classifies the update under Item 2.02 (Results of Operations and Financial Condition). BioLife’s common stock trades on the Nasdaq under the symbol BLFS.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioLife Solutions (BLFS) disclose in this 8-K?

The company announced it issued a press release with unaudited financial results and operational highlights for Q3 ended September 30, 2025.

Which period does the BLFS update cover?

The update covers the third quarter ended September 30, 2025.

Where can I find the detailed Q3 2025 results for BLFS?

Details are in the press release furnished as Exhibit 99.1 to the 8-K.

What 8-K item applies to this BLFS filing?

Item 2.02: Results of Operations and Financial Condition.

What is BioLife Solutions’ trading symbol and exchange?

The common stock trades as BLFS on The Nasdaq Stock Market LLC.

Is the press release in this 8-K audited?

The company states the financial results in the press release are unaudited.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/06/2025 - 04:08 PM Learn about SEC filing dates

false0000834365Nasdaq00008343652025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

BioLife Solutions, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-36362

94-3076866

(State or other jurisdiction of  incorporation)

(Commission File Number)

(IRS Employer Identification No.)

3303 Monte Villa Parkway,

Bothell, WA 98021

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (425) 402-1400

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

			o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
			o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
			o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
			o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading symbol			Name of exchange on which registered
Common Stock, par value $0.001 per share			BLFS			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition.

On November 6, 2025, BioLife Solutions, Inc. (the “Company”) issued a press release announcing unaudited financial results and operational highlights for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press release, dated November 6, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			BioLife Solutions, Inc.
Date: November 6, 2025			By:			/s/ Troy Wichterman
						Name: Troy Wichterman
						Title: Chief Financial Officer